ClinicalTrials.gg
Status unknownNCT04955873Updated Aug 10, 2021

Ridge Preservation Using Xenogenic Bone Graft and Pre-hydrated Collagen Membrane

An interventional study of Treatment of the dental extraction socket using newly-released biomaterials and Treatment of the dental extraction socket using well-known biomaterials in Alveolar Bone Resorption and Edentulous Alveolar Ridge, sponsored by Fondazione Bruno Kessler. Status unknown at 5 sites in Italy. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2021-08-10.

Sponsored by Fondazione Bruno Kessler · Not applicable, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Aug 2021), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
45
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Bone Resorption with a site in Italy — 1 open to participants now, 1 under way, none of them phase 3. Bone Resorption · Italy.

Started
2021
with 1 other
No phase
8 of 11
1 open now
Registered
6th of 11
by date
Lead sponsor
1 of 11
Fondazione Bruno Kessler

Among the 11 studies in Bone Resorption with a site in Italy, this one is one of 2 that started in 2021, is one of 8 with no phase, and was the 6th registered.

Bone Resorption

166 studies on the registry are indexed under Bone Resorption; 27 are open to participants now.

Browse Bone Resorption studies →

Open to participants now

1 of the 11 studies in Bone Resorption with a site in Italy is open now. Recruiting first, the newest first:

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 19 Bone Resorption studies recruiting now, 9 (47%) set no upper age limit and 5 (26%) stop at 75 or younger; none take children under 18; 9 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Bone Resorption with a site in Italy, or all of them as a file.
02

Study summary

This pilot multicentric randomized controlled clinical trial is aimed at evaluating the composition of the new-formed tissue into the dental socket after 6 months from tooth extraction and the application of a combination of xenograft bone granules and collagen membrane. Extraction sites will be either grafted with Dentsply Symbios Xenograft Granules and covered with Dentsply Symbios pre-hydrated Collagen Resorbable Membrane or grafted with Geistlich Bio-Oss Collagen and covered with Geistlich Bio-Gide membrane. Results will be compared to spontaneous socket healing.

Read the detailed description

Rational

Socket preservation techniques are effective in mitigating the dimensional changes of the alveolar socket that spontaneously occur after tooth extraction (Avila-Ortiz G, et al. 2019). However, there is insufficient information regarding the type and quality of the newly formed tissue at the extraction site before implant positioning.

Study design

This study is a three-arm multicentric randomized trial that will evaluate the bone healing following ridge preservation of extraction sockets using two different combinations of commercially available xenograft bone granules and collagen membranes available in the market. Results will be compared to tissues obtained from spontaneous healing. A total of 45 participants (15 in each arm) is expected.

Study protocol

Patients, satisfying inclusion criteria and having signed study informed consent, will be randomly allocated to three study groups, receiving the following treatments at the time of tooth extraction:

  • Group A: grafting of postextraction socket with Dentsply Symbios Xenograft granules covered with Dentsply Symbios pre-hydrated Collagen Resorbable Membrane (Test - Group A)
  • Group B: grafting of postextraction socket with Geistlich Bio-Oss Collagen and covering with Geistlich Bio-Gide Collagen membrane (Active comparator - Group B)
  • Group C: no further treatment of the postextraction socket (spontaneous healing, Control - Group C) After 6 months from the extraction, radiographic examinations will be performed and the implant surgery will take place.

On the day of the surgery the width of keratinized mucosa at socked site will be registered. Then, following loco-regional anesthesia, a soft tissue sample of 3 mm in diameter will be obtained using a circular punch at the site intended to receive the implant. Subsequently, a flap will be elevated. Using a trephine drill a 3 mm in diameter block of hard tissue with a length of 5- 6 mm will be collected. The preparation of the implant site will be then carried out until the desired diameter and length are reached for the insertion of the corresponding implant. Torque at implant insertion will be registered.

Once the implant has been inserted, the healing abutment will be positioned and soft tissues will be sutured with single sutures. The prosthetic rehabilitation will be completed after osseointegration, approximately 3 months after the implant surgery.

Histological analysis of soft tissue and hard tissue biopsies

Tissue samples will be immediately fixed in formalin after collection. Histological analysis will be performed on formalin-fixed paraffin-embedded tissue sections, to determine the quantity and quality newly formed tissue and the remaining fraction of the implanted biomaterials.

More specifically, the collected tissue biopsies will be fixed in 4% buffered formalin, decalcified into ethylenediaminetetraacetic acid (EDTA) (if necessary), dehydrated and included in paraffin. Serial sections, including the central portion of the biopsy, will be prepared and colored in hematoxylin and eosin. Vascular structures will be identified by CD34 (Cluster of differentiation 34, hematopoietic progenitor cell antigen) antibody. Portions occupied by mineralized bone (lamellar bone, trabecular bone), osteoid (partially mineralized connective tissue matrix rich in collagen), bone marrow (adipocytes and vascular structures), fibrous tissue (unorganized collagen fibers, cells and vessels), biomaterial granules and residual tissue (unidentified tissue elements, preparation artifacts) will be characterized by morphometric measurements performed according to the protocol described by Lindhe et al. (Clin. Oral Impl. Res.2014;25:786-790). Soft tissues characterization will include the analysis of the structural composition of epithelial and connective tissues, the quantification of the amount micro-vessels in connective tissue, the definition of the inflammatory cell types, and the collagen tissue content according to protocols described in Tomasi et al. (J Clin Periodontol. 2016;43:816-24).

Data analysis and statistics

Data analysis will be aimed at detecting statistically significant differences in tissue composition between the group A in respect to the most appropriate of the two remaining groups (e.g. the percentage of bone tissue in the test group will be compared with that of control group C while the percentage of residual biomaterial six months after implantation will be compared with the active control B). Statistically significant differences with p\<0.05 will be considered.

Data normality will be verified with the Shapiro-Wilk test. Outcome variables for each of three groups will be expressed by means of mean ± standard deviation for continuous variables with normal distribution, or by means of median and value at the 25th and 75th percentile for variables with non-normal distribution. Parametric or non-parametric statistical tests will then be applied to compare between groups, according to data normality.

03

Conditions studied

  • Alveolar Bone Resorption
  • Edentulous Alveolar Ridge

Browse trials for

Keywords

  • Ridge preservation
  • Xenograft
  • Collagen membrane
  • Socket preservation
  • Socket management
  • Biomaterial
  • Histomorphometry
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • have at least one tooth (from the central incisor to the second permanent molar) to be extracted and replaced with an endosseous implant;
  • no need of a temporary prosthesis;
  • availability to participate to the follow-up;
  • sign the study and consent to data treatment;

Exclusion criteria

Exclusion Criteria:

  • less than 20 years;
  • known allergy to collagen or bone graft material;
  • to implant therapy;
  • ongoing bisphosphonate-based therapy;
  • ongoing high-dose therapy;
  • relevant co-morbidities of the maxillary bones that interfere with bone remodeling (degenerative bone diseases, osteomyelitis at the extraction site or surrounding areas, subacute mandibular osteitis, local microvascular disorders);
  • smoking;
  • pregnancy;
  • metabolic diseases (diabetes, hyperparathyroidism);
  • systemic bone diseases;
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
45 participants (estimated)

Study arms

  • Experimental
    Test - Group A - Dentsply biomaterials

    Dental extraction socket treated with the combined use of the xenogenic bone granules "Dentsply Sirona Symbios Xenograft Granules" and the resorbable collagen membrane "Dentsply Sirona Symbios Collagen Membrane SR".

    Device: Treatment of the dental extraction socket using newly-released biomaterials

  • Active comparator
    Active comparator - Group B - Geistlich biomaterials

    Dental extraction socket treated with the combined use of the xenogenic bone granules "Geistlich Bio-oss Collagen" and the resorbable collagen membrane "Geistlich BioGide".

    Device: Treatment of the dental extraction socket using well-known biomaterials

  • No intervention
    Control - Group C - Spontaneous healing

    Spontaneous postextraction alveolar healing

Interventions

  • DeviceTreatment of the dental extraction socket using newly-released biomaterials

    Treatment of the dental extraction socket with the combined use with the combined use of a newly-released xenogenic bone granules and a resorbable collagen membrane.

  • DeviceTreatment of the dental extraction socket using well-known biomaterials

    Treatment of the dental extraction socket with the combined use of a well-known xenogenic bone granules and a resorbable collagen membrane

06

What researchers measure

Primary outcomes

  1. Composition of new-formed hard tissue into the post-extractive socket

    Amount of mineralized bone, residual biomaterial, fibrous tissue

    Time frame: Six months after surgery

  2. Composition of new-formed soft tissue over the post-extractive socket

    Amount of epithelial tissue, connective tissue, of neovascularization, inflammatory cells, residual collagenic biomaterial

    Time frame: Six months after surgery

Secondary outcomes

  1. Implant torque at insertion

    Dynamometric measurement of the insertion torque at implant placement

    Time frame: Six months after surgery, at implant insertion.

  2. Width of keratinized mucosa

    Extension of keratinized mucosa in the bucco-lingual direction

    Time frame: Six months after surgery, at implant insertion.

07

Study locations

5 of 5 sites recruiting
  • Studio Odontoiatrico Maia Dentis
    Merano, Bolzano 39012, Italy
    Recruiting
    • Antonio Bonaccorso, MD · Contact
    • Teresa R Tripi, MD · Sub investigator
  • Studio Medico Dentistico Dott. Mandelli
    Pioltello, Milano 20096, Italy
    Recruiting
    • Federico Mandelli, MD · Contact
  • Studio Dentistico Bressan Associati Di Bressan Eriberto - Bressan Giuseppe - Bressan Paolo
    Chions, Pordenone 33083, Italy
    Recruiting
    • Eriberto Bressan, MD, Prof. · Contact
  • Studio Dentistico Associato Tomasi-Ghensi-Varotto
    Cembra, Trento 38054, Italy
    Enrolling by invitation
  • Studio Dentistico Donati Di Donati Andrea & Mauro
    Perugia, 06121, Italy
    Recruiting
    • Mauro Donati · Contact
08

References and documents

Publications

  • Avila-Ortiz G, Chambrone L, Vignoletti F. Effect of alveolar ridge preservation interventions following tooth extraction: A systematic review and meta-analysis. J Clin Periodontol. 2019 Jun;46 Suppl 21:195-223. doi: 10.1111/jcpe.13057. Erratum In: J Clin Periodontol. 2020 Jan;47(1):129. doi: 10.1111/jcpe.13212. PubMed 30623987 ↗
  • Lindhe J, Cecchinato D, Donati M, Tomasi C, Liljenberg B. Ridge preservation with the use of deproteinized bovine bone mineral. Clin Oral Implants Res. 2014 Jul;25(7):786-90. doi: 10.1111/clr.12170. Epub 2013 Apr 4. PubMed 23556467 ↗
  • Tomasi C, Tessarolo F, Caola I, Piccoli F, Wennstrom JL, Nollo G, Berglundh T. Early healing of peri-implant mucosa in man. J Clin Periodontol. 2016 Oct;43(10):816-24. doi: 10.1111/jcpe.12591. Epub 2016 Jul 28. PubMed 27329966 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2021; primary completion for Feb 2023, 18 months later.

Of 82 non-industry interventional studies with no phase under Bone Resorption, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 35. This study's planned 18 months is below that.

Counting every sponsor, half of 83 studies reached it within 23 months; a quarter within 12 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 5, 2021
First posted
Jul 9, 2021
StartEst.
Aug 2021
Primary completionEst.
Feb 1, 2023
CompletionEst.
Apr 1, 2023
Last update
Aug 10, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 10, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04955873
Lead sponsor
Fondazione Bruno Kessler
Responsible party
Sponsor
First posted
Jul 9, 2021
Start date
Aug 2021 (estimated)
Primary completion
Feb 1, 2023 (estimated)
Completion
Apr 1, 2023 (estimated)
Last update
Aug 10, 2021

Study contacts

Paolo Ghensi, DDS, PhD
Contact
dr.ghensi@gmail.com
+39 0461 282775
Francesco Tessarolo, PhD
Contact
francesco.tessarolo@unitn.it
+39 0461 282775
Francesco Tessarolo, PhD
principal investigator · Bruno Kessler Fundation, Trento Italy
Paolo Ghensi, DDS, PhD
principal investigator · Università degli Studi di Trento

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion